Activated legal provisions requiring NHS England to maintain registers of local pharmaceutical service performers effective October 2026.

This Order brings section 208 of the Health and Social Care Act 2012 into full force on 1 October 2026.

It empowers NHS England to establish and maintain formal lists of persons who perform or assist in the provision of local pharmaceutical services.

The Order applies to the Secretary of State for Health and Social Care and impacts the regulatory oversight of pharmaceutical contractors and their staff under the National Health Service Act 2006.

Added meningitis, tetanus, diphtheria, and polio vaccines to the list of medicines subject to zero or nominal NHS reimbursement in England starting 20 July 2026.

These regulations amend the National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013 to include several additional vaccines in the list of medicines eligible for zero or nominal reimbursement.

They apply to NHS pharmaceutical service providers in England who administer centrally purchased vaccines for meningococcal disease (groups A, C, W, Y, and B), tetanus, diphtheria, and polio.

The instrument ensures that where the government has already paid for the supply of these vaccines, pharmacies do not receive a standard purchase price reimbursement for them.

Established mandatory chemical purity standards and identification criteria for magnesium L-threonate monohydrate used in food supplements in England.

These Regulations establish the statutory purity criteria for magnesium L-threonate monohydrate when used as a mineral source in food supplements.

The Secretary of State for Health and Social Care mandates that this substance must meet specific chemical identities, assay percentages for magnesium and L-threonate, and maximum limits for impurities like arsenic, lead, and oxalic acid.

These requirements apply to any person or business producing or marketing this substance for food supplement use within England.

The Regulations updated the payment percentages within the statutory scheme governing costs associated with branded health service medicines for periods starting July 2026 and beyond.

These Regulations, made by the Secretary of State for Health and Social Care, amend the Branded Health Service Medicines (Costs) Regulations 2018, which establishes a scheme requiring manufacturers and suppliers of branded medicines for the National Health Service (NHS) to pay amounts based on net sales income; the amendments update specific payment percentages applicable for periods beginning July 1st, 2026, and for subsequent years across England, Wales, Scotland, and Northern Ireland.

The Regulations amended the 2015 rules to clarify charge exemptions for overseas visitors seeking specific NHS treatments and added Hantavirus disease to the Schedule 1 list of exempt conditions, applying retrospectively to May 1st, 2026.

These Regulations amend the 2015 rules governing National Health Service charges for overseas visitors in England by introducing and clarifying exemptions related to specific diseases and the circumstances under which visitors seek treatment.

Specifically, the amendment clarifies that charges must generally be applied if an overseas visitor came to the UK explicitly for the diagnosis or treatment of a condition listed in Schedule 1, unless the travel was state-approved or funded.

Furthermore, the Regulations add Hantavirus disease, including its severe forms, to the list of conditions exempt from visitor charges, ensuring treatment is free for overseas visitors, and mandates that charges made since May 1st, 2026, for this specific disease must not be recovered or must be repaid.

Added hantavirus disease and its associated syndromes to the statutory list of notifiable diseases in England.

These Regulations amend the Health Protection (Notification) Regulations 2010 to include hantavirus disease in the list of notifiable diseases in England.

This addition requires registered medical practitioners to notify the relevant local authority if they suspect a patient is suffering from hantavirus disease, including hantavirus pulmonary syndrome or haemorrhagic fever with renal syndrome.

The duty also extends to operators of diagnostic laboratories who identify evidence of the causative agent in human samples.

Amended NHS GP contracts to remove online consultation limits and mandate electronic registration and screening data sharing.

These Regulations amend the standard contracts for General Medical Services and Personal Medical Services in England to modify how patients interact with GP practices and pharmacies.

The instrument directs GP contractors to stop limiting online consultation requests during core hours, requires them to provide next-day responses for non-urgent matters, and mandates cooperation with the national Lung Cancer Screening Programme.

It applies to all NHS GP contractors and NHS England, establishing new duties for data sharing, staff survey participation, and the use of digital registration tools.

The Regulations amended the 2014 rules to subject temporary treatment of injury or disease at sporting and cultural events to CQC regulation, while phasing the commencement from September 2026 to December 2027.

These Regulations, made by the Secretary of State, amend the 2014 Health and Social Care Act (Regulated Activities) Regulations by removing two specific exemptions from the definition of 'regulated activities' concerning the temporary treatment of disease, disorder, or injury provided at sporting grounds, gymnasiums, or during cultural events; consequently, such treatments will become subject to regulation by the Care Quality Commission, while an exception for incidental transport services during these events is retained, with amendments coming into force in phases starting September 2026 and fully by December 2027 across England and Wales.